• ÆäÀ̽ººÏ °øÀ¯
  • Æ®À§ÅÍ °øÀ¯
  • ¹ÌÅõµ¥ÀÌ °øÀ¯
  • URLº¹»ç
  • ´õº¸±â
  • °ü½ÉÀÇ·áÁø µî·Ï

ÀÌÀº½Å

  • Áø·á°ú

    À¯¹æ³»ºÐºñ¿Ü°ú

  • Àü¹®Áø·áºÐ¾ß

    À¯¹æ¾Ï, À¯¹æÁúȯ, À¯Àü¼º À¯¹æ¾Ï, À¯¹æ¾Ï¼ºÇü¼ö¼ú

  • ´ã´çŬ¸®´Ð

  • °ü·Ã¼¾ÅÍ

    ¾Ïº´¿ø ȨÆäÀÌÁö , À¯¹æ¼¾ÅÍ

ÀÌÀº½Å

ÀÌÀº½Å ±³¼öÀÇ Áø·á½Ã°£Ç¥ Áø·á¿¹¾à

Áø·á°ú/¼¾ÅÍ ¿ù È­ ¼ö ¸ñ ±Ý Åä Àü¹®Áø·á°ú¸ñ
À¯¹æ³»ºÐºñ¿Ü°ú -
¿ÀÀü
¿ÀÈÄ
-
Á¾ÀÏ
- À¯¹æ¾Ï, À¯¹æÁúȯ, À¯Àü¼º À¯¹æ¾Ï, À¯¹æ¾Ï¼ºÇü¼ö¼ú
À¯¹æ¼¾ÅÍ
¿ÀÀü
- -
¿ÀÈÄ
- - À¯¹æ¾Ï, À¯¹æÁúȯ, À¯Àü¼º À¯¹æ¾Ï, À¯¹æ¾Ï¼ºÇü¼ö¼ú

ÀÌÀº½Å ±³¼öÀÇ »ó¼¼Á¤º¸

ÇзÂ

more
  •  ~  2005 .02  :  °æºÏ ´ëÇб³ Àǰú´ëÇÐ Á¹¾÷
  •  ~  2020 .08  :  ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú ¼®»ç
  • 2020 .09  ~   :  ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¹Ú»ç°úÁ¤ Áß

°æ·Â

more
  • 2013  ~  2015  :  ¼­¿ï´ëÇб³º´¿ø À¯¹æ¼¾ÅÍ ¿Ü°ú ÀÓ»ó °­»ç
  • 2016  ~  2019  :  ¼­¿ï´ëÇб³º´¿ø À¯¹æ¼¾ÅÍ ¿Ü°ú Áø·áÁ¶±³¼ö
  • 2019  ~  2020  :  ¼­¿ï´ëÇб³º´¿ø °­³²¼¾ÅÍ ¿Ü°ú ¿Ü·¡±³¼ö
  • 2016 .12  ~  2017 .01  :  Dana Farber/Brigham and Women¡¯s Cancer Center, Boston, MA. À¯¹æ Á¾¾ç ¿Ü°ú ´Ü±â¿¬¼ö

¼ö»ó³»¿ª

more
  • 2017  :  Young investigator award, Global Breast Cancer Conference

ÇÐȸȰµ¿

more
  •  ~   :  ´ëÇѿܰúÇÐȸ Á¤È¸¿ø
  •  ~   :  Çѱ¹À¯¹æ¾ÏÇÐȸ Á¤È¸¿ø
  •  ~   :  Çѱ¹À¯¹æ¾ÏÇÐȸ À¯¹æ¾Ï¼ºÇü¼ú ¿¬±¸È¸ °£»ç

±¹³»È°µ¿

more
  • 2014 .03  ~   :  Presentation at <SISSO 2014> Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years
  • 2017 .03  ~   :  Presentation at <SISSO 2017> An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients. -> Best Poster Presentation award
  • 2018 .03  ~   :  Presentation at <SISSO 2018> Clinical application of multigene panel testing and association between germline mutations in predisposition genes and clinicopathological factors in patients with high risk for hereditary breast cancer. -> Best Poster Presentation award
  • 2017 .05  ~   :  Presentation at <GBCC 2017> Clinical application of multigene panel testing and association between germline mutations in predisposition genes and clinicopathological factors in patients with high risk for hereditary breast cancer
  • 2018 .05  ~   :  Presentation at <GBCC 2018> ASSOCIATIONS BETWEEN GERMLINE MUTATIONS IN PREDISPOSITION GENES AND CLINICOPATHOLOGICAL FACTORS INCLUDING BREAST CANCER SUBTYPES AND AGE OF PATIENTS WITH HIGH RISK FOR HEREDITARY BREAST CANCER

±¹¿ÜȰµ¿

more
  • 2013 .12  ~   :  Presentation at <2013 San Antonio Breast Cancer Symposium>, Texas, Clinical benefits of using nomogram for predicting positive resection margins in breast conserving surgery
  • 2014 .12  ~   :  Presentation at <2014 San Antonio Breast Cancer Symposium>, Texas, Discovery of novel amplified genes in primary breast cancer with copy number and gene expression analysis of whole exome and transcriptome sequencing data
  • 2014 .12  ~   :  Presentation at <2014 San Antonio Breast Cancer Symposium>, Texas, Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years
  • 2016 .12  ~   :  Presentation at <2016 San Antonio Breast Cancer Symposium>, Texas, An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients
  • 2017 .09  ~   :  Presentation at <2017 European Breast Cancer Summit>, Italy, An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients
  • 2017 .12  ~   :  Presentation at <2017 San Antonio Breast Cancer Symposium>, Texas, Clinical application of multigene panel testing and association between germline mutations in predisposition genes and clinicopathological factors in patients with high risk for hereditary breast cancer

³í¹®

more
  • [SCI] (Identifying the potential long-term survivors among breast cancer patients with distant metastasis)
  • [SCI] (Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer)
  • [SCI] (Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery)
  • [SCI] (Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide dat)
  • [SCI] (Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer)
  • [SCI] (Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer)
  • [SCI] (Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis)
  • [SCI] (Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signalling for cell proliferation)
  • [SCI] (Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? - Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes Before Breast Cancer Surgery)
  • [SCI] (The treatment outcomes and the use of adjuvant therapies in breast cancer patients with severe co-morbidities)
  • [SCI] (Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer)
  • [SCI] (In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients)
  • [SCI] (Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence)
  • [SCI] (Effect of cosmetic outcome on quality of life after breast cancer surgery)
  • [SCI] (The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women)
  • [SCI] (Immediate Breast Reconstruction vs. Mastectomy Alone in Locally Advanced Breast Cancer; Local Recurrence and Distant Recurrence)
  • [SCI] (Actual Conversion Rate from Total Mastectomy to Breast Conservation after Neoadjuvant Chemotherapy for Stages II&#8211;III Breast Cancer Patients)

Àú¼­

more
  • Personalized Treatment of Breast Cancer (Japan, Editor : Masakazu Toi, Eric Winer, John Benson, Suzanne Klimberg)
  • À¯¹æ ÃÊÀ½ÆÄ Áø´ÜÇÑ 2ÆÇ

ÃÖÁ¾¼öÁ¤ÀÏ : 2020.11.30